The market assigns a significant premium to PLXS relative to its HMLV peers, with a forward P/E of 32.1x versus BHE's 121x (distorted by low earnings) and SANM's 46x. This premium appears justified by the higher-margin, more resilient Healthcare/Life Sciences and Aerospace/Defense mix, which supports a more durable earnings stream. However, the PEG of 4.4 suggests that the current price already discounts substantial growth, and any shortfall in program ramps could lead to multiple compression. Investors should monitor whether the growth implied by the multiple is achievable given the recent EPS miss.

The stability of gross margin around 10% is a hallmark of the EMS model, but the sequential decline in operating margin indicates that the revenue surge is not translating into proportional operating leverage. The EPS miss versus consensus ($2.32 actual vs. $2.55 estimate) aligns with this margin pressure, possibly due to program mix or ramp inefficiencies. Net margin of 3.3% in 2026Q3 is below the 4.9% seen in 2025Q4, highlighting that the bottom line is more sensitive to operating costs and SBC. The true earning power may be better reflected by operating margin, which remains below the 5% threshold that would signal robust utilization.

Despite revenue growth, ROIC remains stagnant at approximately 3%, indicating that the company is not compounding returns on its invested capital. The asset turnover of 0.37x is low, reflecting the capital-intensive nature of manufacturing, but the more concerning driver is the thin net margin of 3.3%. ROE of 2.8% is similarly subdued, and while leverage is low, it does not amplify returns meaningfully. This suggests that the business model, while stable, is not generating excess returns, and investors should question whether the premium valuation is justified by such modest capital efficiency.

The improvement in CCC from 168 days in 2024Q2 to 98 days in 2026Q3 is driven by a reduction in DIO from 160 to 111 days, suggesting better inventory management. However, the recent quarter saw a sharp swing in working capital, with operating cash flow lagging net income (OCF/NI of 0.60). DSO of 58 days is relatively stable, but the negative FCF margin highlights that growth is consuming cash, likely due to inventory build for new programs. This warrants monitoring, as the HMLV model carries risk of trapped cash in specialized components.

The increase in leverage is modest and remains far below peers like JBL (2.22) and FLEX (0.84), reflecting a conservative capital structure. Interest coverage of 15.25x, though down from 21.58x in 2025Q4, is still robust, indicating that debt service is not a concern. The D/EBITDA of 13.15x in 2026Q3 is elevated due to a temporary dip in EBITDA, but this is likely a timing issue. The low leverage provides financial flexibility to weather downturns or fund growth, but investors should monitor whether the company is underutilizing its balance sheet to drive higher returns.

The current ratio has declined from 1.58 a year ago, and the quick ratio of 0.72 suggests that excluding inventory, the company would struggle to cover current liabilities. This is typical for manufacturers, but the high DIO of 111 days means that inventory is a significant component of liquidity. In a severe downturn, the specialized nature of the inventory could impair its realizable value, potentially stressing liquidity. However, the low debt levels and cash position of $314.1M provide a buffer, though the negative FCF margin in 2026Q3 indicates that internal cash generation is not currently sufficient to fund growth.